> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Galaxy Therapeutics Completes FDA Filing for Aneurysm Device
- URL: https://www.fdaweb.com/galaxy-therapeutics-completes-fda-filing-for-aneurysm-device/
- Published: 2026-04-27T12:00:00.000Z
- Updated: 2026-09-14T13:38:08.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5161049

Galaxy Therapeutics has submitted the final module of a PMA for its SEAL device, a treatment designed for patients with wide-neck bifurcation brain aneurysms. The filing completes the company’s modular PMA submission, a regulatory pathway that allows device makers to submit sections of an application incrementally. The SEAL device is intended to treat complex aneurysms that occur at vessel branch points in the brain — cases that the company says are often more difficult to manage with existing technologies.

The application is supported by data from the wide-neck bifurcation aneurysm cohort of the SEAL IT IDE trial, which enrolled 163 patients across U.S. neurointerventional centers. According to the company, the study was designed to reflect real-world clinical practice, including patients with a broad range of aneurysm sizes and anatomical challenges.